China-Focused Life Science Investor Acquires 37% of NovaBay for $28M Post author:Sam Post published:December 27, 2017 Post category:BioPharma After the transaction, it will be NovaBay’s largest shareholder with 6.6 million shares, 37% of the total. Source: BioSpace You Might Also Like Superstar Investors Jump in on Celgene Spinout Celularity's $250M Funding Round February 15, 2018 Amazon in Exploratory Talks With Mylan, Novartis About Pharma Entry November 30, 2017 Bay Area's CytomX Surges as Bristol-Myers Squibb Signs Up for 8 More Projects With $200 Million Upfront in Deal Totaling $5 Billion March 19, 2017
Bay Area's CytomX Surges as Bristol-Myers Squibb Signs Up for 8 More Projects With $200 Million Upfront in Deal Totaling $5 Billion March 19, 2017